Investors have been agonizing over how big a threat China poses to the global economy, but they may be looking in the wrong place.
Consumer prices in Japan were unchanged from a year earlier in July, defying expectations for a fall.
Today the Dow went up 2% in the last 45 minutes. THAT is ridiculous.
Activist investor Carl Icahn became the top shareholder in mining company Freeport-McMoRan.
On the tenth anniversary of Hurricane Katrina, New Orleans is far better protected now than it was then. The same can't be said about Miami.
"Fast Money" traders discussed how to play Apple, Amazon and Tesla after all three stocks popped on Thursday.
Washington Wizards, Capitals, and Mystics owner Ted Leonsis discusses how virtual reality could change the sports world.
It may be down, but today’s action has “Mad Money” host Jim Cramer questioning whether this sector is really out.
Jim Cramer saw the wrong stocks lead and the right stocks lag on Thursday's rally. That's OK because it just took major risk off the table.
A judge ruled on Thursday that CEO David Murdock must pay his shareholders $148.2 million in damages.
It's not 2008 anymore (when the Fed set its current target for rates). Time for the Fed to normalize rates, says Jack Ablin.
Tesla just made Consumer Reports history with a perfect score of 100 for the P85D Model S.
Bill Ackman's Pershing Square fell 13.1 percent this month, leaving the fund down 4.3 percent for the year.
The U.S. Treasury said it had reached an agreement with UBS for the Swiss bank to pay a $1.7 million for "apparent violations" to U.S. sanctions.
Following a recent selloff in U.S. equities, market watchers believe a bottom may be in, clearing the way for stocks to continue their march higher.
Bottled water sales keep growing and are now on track to surpass soda sales by 2017; that might not be bad news for Coke and Pepsi.
On Monday, one in seven of the people on Earth used Facebook, the company announced Thursday.
Are you the world's worst market timer? That's OK, because you've still made money in stocks—as long as you didn't sell.
Amgen is getting approval by the FDA for a new cholesterol drug, reports CNBC's Meg Tirrell.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the bounce back in today's markets as crude prices jump and equities soar.